hantavirus vaccine

The hantavirus vaccine program at Phylex BioSciences focuses on the development of an AI-derived mRNA nanoparticle vaccine specifically targeting the Andes hantavirus (ANDV), the primary causative agent of Hantavirus Pulmonary Syndrome (HPS) in South America. The vaccine utilizes a proprietary platform where mRNA encodes a self-assembling nanoparticle that displays 60 copies of a computationally optimized viral antigen. This design is intended to mimic the structural features of the virus to elicit a potent and durable neutralizing antibody response. Developed using deep learning AI tools in response to zoonotic threats and specific outbreaks (such as the MV Hondius cruise ship incident), the vaccine aims to provide rapid protection and prevent severe cardiopulmonary and neurological symptoms associated with viral dissemination. As of mid-2026, the program is in the research and preclinical stage, with the design completed and ready for manufacturing and in vivo testing.

Other names

Andes hantavirus vaccineAndes virus vaccinemRNA nanoparticle hantavirus vaccine